Earlier this month, study results showed that molnupiravir, Merck’s investigational antiviral pill, cut hospitalization rates of Covid-19 patients by about half. Molnupiravir is the first oral ...

Developed by Merck and Ridgeback Biotherapeutics, molnupiravir popped up in various reports last year, and it was also the cause of some controversy last spring. The drug was studied on humans and ...

Shares in Merck lost 3.5% of their value after the announcement, while Pfizer – already making big profits from its BioNTech-partnered COVID-19 vaccine – rose almost 6%.

FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by ...

Merck & Co and Ridgeback's oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with mild to moderate COVID-19 who are at increased risk of ...

Merck has conducted interim clinical trials of its oral medicine, molnupiravir, and will soon seek approval for its emergency use in the United States. Global demand for the medicine is expected ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

By Sachin Ravikumar (Reuters) -A Bangladeshi drugmaker will soon begin selling the world’s first generic version of Merck’s COVID-19 pill, molnupiravir, which has been touted as a potential ...

The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir. In addition, Kishida announced last ...